Cypriot Group Develops Non-Invasive, Prenatal Down Syndrome Dx; Creates Startup to Market Test | GenomeWeb

By Ben Butkus

A group of scientists from Cyprus has combined methylated DNA immunoprecipitation and quantitative real-time PCR into a non-invasive, prenatal test that can diagnose Down syndrome with 100 percent sensitivity and specificity, according to a paper published online this week in Nature Medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.